

NoAb BioDiscoveries, Inc. Launches Serial Cerebrospinal Fluid (CSF) and Plasma Collection in Freely Moving Rats

March, 2008

Toronto, Canada

In Vivo evaluation of drug penetration into the CNS is vital for characterizing CNS-targeted compounds, and offers several advantages over *In Vitro* models, such as bovine brain endothelial cell cultures. For several years, our clients have relied on our *In Vivo* Serial CSF & plasma collection model in anaesthetized animals for estimation of blood brain barrier penetration of their compounds. In this model, CSF & plasma are collected continuously from a single, catheterized animal over an extended time. The ratio of areas under the CSF and plasma concentration vs. time curves gives an estimation of brain penetration of the drug candidate. As part of our commitment to offer cutting-edge discovery services, we have refined our model to be used on freely moving animals, thereby avoiding any possible interactions with or effects from the anaesthetics. The service is currently being offered in rats, and plans to validate the model in guinea pigs are underway.

More information about our *In Vivo* pharmacokinetics services can be found at:
http://www.noabbiodiscoveries.com/html/invivo/invivo_disc.html

NoAb BioDiscoveries is a discovery stage contract research organization, engaged in developing and providing novel tools for accelerating the drug discovery process. NoAb provides a broad suite of *In Vitro* ADME assays and *In Vivo* drug disposition studies in rodents, helping our clients to profile and shape their compounds into the best candidates for further development.

www.noabbiodiscoveries.com

For more information, please contact:

David K.H. Lee, Ph.D.
Chief Scientific Officer
NoAb BioDiscoveries, Inc.
905-814-5238 ext. 222
dkhlee@noabbiodiscoveries.com